Myriad Genetics to Participate in Goldman Sachs Healthcare Conference
June 07, 2023 16:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, June 07, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, president and CEO, will...
Myriad Genetics Highlights Latest Oncology Portfolio Advancements and New Data at ASCO 2023
June 01, 2023 08:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, June 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be highlighting new studies and the recent expansion...
Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad Genetics
May 31, 2023 08:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, May 31, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has named Adam Brufsky, MD, PhD, FACP,...
Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer
May 24, 2023 16:05 ET
|
Myriad Genetics, Inc.
Biomarker offers another companion diagnostic option to establish eligibility for FDA-approved drug ELAHERE® SALT LAKE CITY, May 24, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a...
Myriad Genetics Earns 2023 Great Place to Work Certification™
May 08, 2023 16:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, May 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has achieved the Great Place to Work®...
Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range
May 03, 2023 16:05 ET
|
Myriad Genetics, Inc.
Highlights: First quarter testing volumes grew 21% year-over-year and 10% sequentially, excluding contributions from the SneakPeek® Early Gender DNA Test.In the first quarter: Hereditary cancer...
Myriad Genetics to Participate in BofA Securities Healthcare Conference
May 02, 2023 16:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, May 02, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will be participating in the upcoming...
Myriad Genetics to Release First Quarter Financial Results on May 3, 2023
April 26, 2023 16:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, April 26, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its first quarter earnings conference call on...
77% of Americans have used addictive behaviors or unhealthy coping mechanisms to manage their mental health, according to Myriad Genetics nationwide survey
April 19, 2023 07:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, April 19, 2023 (GLOBE NEWSWIRE) -- From restricted or binge eating to excessive gambling to extreme social media use, 77% of Americans surveyed say they have used at least one...
Myriad Genetics and Intermountain Precision Genomics Now Offer Solid Tumor Testing in All 50 States with Latest NY State Certification
April 18, 2023 08:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, April 18, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Intermountain Precision Genomics, a service of...